Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié & Christos Chouaïd. (2020) Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date. OncoTargets and Therapy 13, pages 5691-5706.
Read now
Read now
Maksym O. Chekanov, Olga V. Ostrynska, Sergii S. Tarnavskyi, Anatoliy R. Synyugin, Nadiia V. Briukhovetska, Volodymyr G. Bdzhola, Alexander E. Pashenko, Andrey A. Fokin & Sergiy M. Yarmoluk. (2014) Design, synthesis and biological evaluation of 2-aminopyrimidinones and their 6-aza-analogs as a new class of CK2 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 29:5, pages 639-646.
Read now
Read now
Maksym O. Chekanov, Olga V. Ostrynska, Anatoliy R. Synyugin, Volodymyr G. Bdzhola & Sergiy M. Yarmoluk. (2014) Design, synthesis and evaluation of 2-phenylisothiazolidin-3-one-1,1-dioxides as a new class of human protein kinase CK2 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 29:3, pages 338-343.
Read now
Read now
Stefan Fischer, Solveigh C Koeberle & Stefan A Laufer. (2011) p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011). Expert Opinion on Therapeutic Patents 21:12, pages 1843-1866.
Read now
Read now
John Porter. (2010) Small molecule c-Met kinase inhibitors: a review of recent patents. Expert Opinion on Therapeutic Patents 20:2, pages 159-177.
Read now
Read now
Articles from other publishers (67)
Die Jiang, Ting Xu, Lei Zhong, Qi Liang, Yonghe Hu, Wenjing Xiao & Jianyou Shi. (2023) Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases. European Journal of Medicinal Chemistry 257, pages 115535.
Crossref
Crossref
Sarah Nevins, Callan D. McLoughlin, Alfredo Oliveros, Joshua B. Stein, Mohammad Abdur Rashid, Yannan Hou, Mi‐Hyeon Jang & Ki‐Bum Lee. (2023) Nanotechnology Approaches for Prevention and Treatment of Chemotherapy‐Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors. Small.
Crossref
Crossref
Menier Al-Anazi, Melati Khairuddean, Belal O. Al-Najjar, Mohammad Murwih Alidmat, Nik Nur Syazni Nik Mohamed Kamal & Musthahimah Muhamad. (2022) Synthesis, anticancer activity and docking studies of pyrazoline and pyrimidine derivatives as potential epidermal growth factor receptor (EGFR) inhibitors. Arabian Journal of Chemistry 15:7, pages 103864.
Crossref
Crossref
Esther Carrasco, Patricia Gomez-Gutierrez, Pedro M. Campos, Miguel Vega, Angel Messeguer & Juan Jesus Perez. (2022) Structure-Activity Studies of Novel Di-substituted [1,2,5]oxadiazolo [3,4-b]pyrazine Analogs Targeting the A-loop Regulatory Site of p38
MAP Kinase. Current Medicinal Chemistry 29:9, pages 1640-1653.
Crossref
Crossref
Przemysław Biegański, Martina Godel, Chiara Riganti, Daniel Fábio Kawano, Joanna Kopecka & Konrad Kowalski. (2022) Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. Bioorganic Chemistry 119, pages 105514.
Crossref
Crossref
Parneet K. Cheema, Shantanu O. Banerji, Normand Blais, Quincy S.-C. Chu, Patrice Desmeules, Rosalyn A. Juergens, Natasha B. Leighl, Brandon S. Sheffield, Paul F. Wheatley-Price & Barbara L. Melosky. (2021) Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Current Oncology 28:6, pages 4552-4576.
Crossref
Crossref
Quan Zheng, Xuan‐Bo Xu, Hao Jin, Wen Zhang & Guo‐Wu Rao. (2021) Synthesis and Anti‐Proliferation Activity Evaluation of Novel 2‐Chloroquinazoline as Potential EGFR‐TK Inhibitors. Chemistry & Biodiversity 18:11.
Crossref
Crossref
Tao Wang, Qiting Zhang, Ning Wang, Ziqi Liu, Bin Zhang & Yufen Zhao. (2021) Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. Current Medicinal Chemistry 28:16, pages 3107-3146.
Crossref
Crossref
Xiaoyang Li, Jingyi Su, Yanru Yang, Wenhua Lian, Zhou Deng, Zaiyou Yang, Guyue Chen, Baoding Zhang, Chao Dong, Xueyan Liu, Li Li, Zheng Wang, Zhiyu Hu, Qingyan Xu & Xianming Deng. (2020) Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry 207, pages 112755.
Crossref
Crossref
Iman A. Mansi, Mahmoud A. Al-Sha'er, Nizar M. Mhaidat, Mutasem O. Taha & Rand Shahin. (2020) Investigation of Binding Characteristics of Phosphoinositide-dependent Kinase-1 (PDK1) Co-crystallized Ligands Through Virtual Pharmacophore Modeling Leading to Novel Anti-PDK1 Hits. Medicinal Chemistry 16:7, pages 860-880.
Crossref
Crossref
Ying Jin, Zhifei Xu, Hao Yan, Qiaojun He, Xiaochun Yang & Peihua Luo. (2020) A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Frontiers in Pharmacology 11.
Crossref
Crossref
Tianrong Zhang, Qianqian Liu & Yujie Ren. (2020) Design, synthesis and biological activity evaluation of novel methyl substituted benzimidazole derivatives. Tetrahedron 76:13, pages 131027.
Crossref
Crossref
Yung‐Jue Bang, Wu‐Chou Su, Martin Schuler, Do‐Hyun Nam, Wan Teck Lim, Todd M. Bauer, Analia Azaro, Ronnie Tung Ping Poon, David Hong, Chia‐Chi Lin, Mikhail Akimov, Samson Ghebremariam, Sylvia Zhao, Monica Giovannini & Brigette Ma. (2019) Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts. Cancer Science 111:2, pages 536-547.
Crossref
Crossref
Valéria Barbosa de Souza & Daniel Fábio Kawano. (2020) Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy. Biochimica et Biophysica Acta (BBA) - General Subjects 1864:1, pages 129448.
Crossref
Crossref
Peng-Cheng Lv, Yu-Shun Yang & Zhong-Chang Wang. (2019) Recent Progress in the Development of Small Molecule c-Met Inhibitors. Current Topics in Medicinal Chemistry 19:15, pages 1276-1288.
Crossref
Crossref
Irfan Khan, Mohd Adil Shareef & C. Ganesh Kumar. (2019) An overview on the synthetic and medicinal perspectives of indenopyrazoles. European Journal of Medicinal Chemistry 178, pages 1-12.
Crossref
Crossref
Jaya Krishna Koneru, Suman Sinha & Jagannath Mondal. (2019) In Silico Reoptimization of Binding Affinity and Drug-Resistance Circumvention Ability in Kinase Inhibitors: A Case Study with RL-45 and Src Kinase. The Journal of Physical Chemistry B 123:31, pages 6664-6672.
Crossref
Crossref
Baohui Qi, Ying Yang, Guowei Gong, Huan He, Xupeng Yue, Xin Xu, Yun Hu, Junming Li, Tao Chen, Xiaobing Wan, Anmian Zhang & Guobiao Zhou. (2019) Discovery of N-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment. European Journal of Medicinal Chemistry 163, pages 10-27.
Crossref
Crossref
Diego Molina, Rodrigo Cossio-Pérez, Cristian Rocha-Roa, Lina Pedraza, Edwar Cortes, Alejandro Hernández & Jorge E. Gómez-Marín. (2018) Protein targets of thiazolidinone derivatives in Toxoplasma gondii and insights into their binding to ROP18. BMC Genomics 19:1.
Crossref
Crossref
Usama M. Ammar, Mohammed S. Abdel-Maksoud & Chang-Hyun Oh. (2018) Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry 158, pages 144-166.
Crossref
Crossref
Rand Shahin, Iman Mansi, Lubna Swellmeen, Tahani Alwidyan, Nabil Al-Hashimi, Yaser Al-Qarar’h & Omar Shaheen. (2018) Ligand-based computer aided drug design reveals new tropomycin receptor kinase a (TrkA) inhibitors. Journal of Molecular Graphics and Modelling 80, pages 327-352.
Crossref
Crossref
Lubna Swellmeen, Rand Shahin, Yusuf Al-Hiari, Amani Alamiri, Alaa Hasan & Omar Shaheen. (2017) Structure based drug design of Pim-1 kinase followed by pharmacophore guided synthesis of quinolone-based inhibitors. Bioorganic & Medicinal Chemistry 25:17, pages 4855-4875.
Crossref
Crossref
Francesco Ansideri, Marcel Dammann, Frank M. Boeckler & Pierre Koch. (2017) Fluorescence polarization-based competition binding assay for c-Jun N-terminal kinases 1 and 2. Analytical Biochemistry 532, pages 26-28.
Crossref
Crossref
Sailu Sarvagalla & Mohane Selvaraj Coumar. 2017. Pharmaceutical Sciences. Pharmaceutical Sciences
1115
1143
.
Chandrakant Bagul, Garikapati Koteswara Rao, Venkata Krishna Kanth Makani, Jaki R. Tamboli, Manika Pal-Bhadra & Ahmed Kamal. (2017) Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5-a]pyrimidines as potential anticancer agents. MedChemComm 8:9, pages 1810-1816.
Crossref
Crossref
Thanyanan Reungwetwattana, Ying Liang, Viola Zhu & Sai-Hong Ignatius Ou. (2017) The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. Lung Cancer 103, pages 27-37.
Crossref
Crossref
Francesco Ansideri, Andreas Lange, Ahmed El-Gokha, Frank M. Boeckler & Pierre Koch. (2016) Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase. Analytical Biochemistry 503, pages 28-40.
Crossref
Crossref
Dianxi Zhu, Qifeng Xing, Ruiyuan Cao, Dongmei Zhao & Wu Zhong. (2016) Synthesis and p38 Inhibitory Activity of Some Novel Substituted N,N′-Diarylurea Derivatives. Molecules 21:5, pages 677.
Crossref
Crossref
Sailu Sarvagalla & Mohane Selvaraj Coumar. 2016. Applied Case Studies and Solutions in Molecular Docking-Based Drug Design. Applied Case Studies and Solutions in Molecular Docking-Based Drug Design
249
277
.
Rand Shahin, Lubna Swellmeen, Omar Shaheen, Nour Aboalhaija & Maha Habash. (2015) Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets. Journal of Computer-Aided Molecular Design 30:1, pages 39-68.
Crossref
Crossref
Tom Baladi, Valentina Abet & Sandrine Piguel. (2015) State-of-the-art of small molecule inhibitors of the TAM family: The point of view of the chemist. European Journal of Medicinal Chemistry 105, pages 220-237.
Crossref
Crossref
Manuj Tandon, Joseph M. Salamoun, Evan J. Carder, Elisa Farber, Shuping Xu, Fan Deng, Hua Tang, Peter Wipf & Q. Jane Wang. (2015) SD-208, a Novel Protein Kinase D Inhibitor, Blocks Prostate Cancer Cell Proliferation and Tumor Growth In Vivo by Inducing G2/M Cell Cycle Arrest. PLOS ONE 10:3, pages e0119346.
Crossref
Crossref
Atli Thorarensen, Mary Ellen Banker, Andrew Fensome, Jean-Baptiste Telliez, Brian Juba, Fabien Vincent, Robert M. Czerwinski & Agustin Casimiro-Garcia. (2014) ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling. ACS Chemical Biology 9:7, pages 1552-1558.
Crossref
Crossref
O. V. Ostrynska. (2014) EFFECT OF INHIBITORS OF PROTEIN KINASE CK2 ON THE ACTIVITY ITS CATALYTIC SUBUNITS ??2? AND ??2??. Biotechnologia acta 7:6, pages 29-39.
Crossref
Crossref
Hala Bakr El-Nassan. (2014) Recent progress in the identification of BRAF inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry 72, pages 170-205.
Crossref
Crossref
Jeffrey R. Simard & Daniel Rauh. 2014. Protein Kinase Inhibitors in Research and Medicine. Protein Kinase Inhibitors in Research and Medicine
147
171
.
S. M. Yarmoluk, A. Yu. Nyporko & V. G. Bdzhola. (2013) Rational design of protein kinase inhibitors. Biopolymers and Cell 29:4, pages 339-347.
Crossref
Crossref
Xiaolun Wang & Kristin Schleicher. 2013. Inhibitors of the Ras superfamily G-proteins, Part B. Inhibitors of the Ras superfamily G-proteins, Part B
41
66
.
Jennifer L. MasonChrysanthe SpaisJean HustenEric ProutyMark S. AlbomSheryl L. MeyerMark A. AtorThelma S. Angeles. (2012) Comparison of LanthaScreen Eu Kinase Binding Assay and Surface Plasmon Resonance Method in Elucidating the Binding Kinetics of Focal Adhesion Kinase Inhibitors. ASSAY and Drug Development Technologies 10:5, pages 468-475.
Crossref
Crossref
Kathrin E. Martz, Angelika Dorn, Benjamin Baur, Verena Schattel, Márcia I. Goettert, Svenja C. Mayer-Wrangowski, Daniel Rauh & Stefan A. Laufer. (2012) Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38α Inhibitors. Journal of Medicinal Chemistry 55:17, pages 7862-7874.
Crossref
Crossref
Xiaolun Wang & Joseph Kim. (2012) Conformation-Specific Effects of Raf Kinase Inhibitors. Journal of Medicinal Chemistry 55:17, pages 7332-7341.
Crossref
Crossref
Jiayin Bao & Sergey N. Krylov. (2012) Volatile Kinetic Capillary Electrophoresis for Studies of Protein–Small Molecule Interactions. Analytical Chemistry 84:16, pages 6944-6947.
Crossref
Crossref
Kathryn Bell, Mihiro Sunose, Katie Ellard, Andrew Cansfield, Jess Taylor, Warren Miller, Nigel Ramsden, Giovanna Bergamini & Gitte Neubauer. (2012) SAR studies around a series of triazolopyridines as potent and selective PI3K? inhibitors. Bioorganic & Medicinal Chemistry Letters 22:16, pages 5257-5263.
Crossref
Crossref
Solveigh C. Koeberle, Stefan Fischer, Dieter Schollmeyer, Verena Schattel, Christian Grütter, Daniel Rauh & Stefan A. Laufer. (2012) Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase. Journal of Medicinal Chemistry 55:12, pages 5868-5877.
Crossref
Crossref
Matthäus Getlik, Christian Grütter, Jeffrey R. Simard, Hoang D. Nguyen, Armin Robubi, Beate Aust, Willem A.L. van Otterlo & Daniel Rauh. (2012) Structure-based design, synthesis and biological evaluation of N-pyrazole, N′-thiazole urea inhibitors of MAP kinase p38α. European Journal of Medicinal Chemistry 48, pages 1-15.
Crossref
Crossref
Robert L. Hudkins, Nadine C. Becknell, Allison L. Zulli, Ted L. Underiner, Thelma S. Angeles, Lisa D. Aimone, Mark S. Albom, Hong Chang, Sheila J. Miknyoczki, Kathryn Hunter, Susan Jones-Bolin, Hugh Zhao, Edward R. Bacon, John P. Mallamo, Mark A. Ator & Bruce A. Ruggeri. (2012)
Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4
H
-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent
. Journal of Medicinal Chemistry 55:2, pages 903-913.
Crossref
Crossref
Pascal Bonnet, Daniel Mucs & Richard A. Bryce. (2012) Targeting the inactive conformation of protein kinases: computational screening based on ligand conformation. Med. Chem. Commun. 3:4, pages 434-440.
Crossref
Crossref
Jeffrey R. Simard & Daniel Rauh. 2012. Chemical Genomics and Proteomics. Chemical Genomics and Proteomics
95
117
.
Jiayin Bao, Svetlana M. Krylova, Derek J. Wilson, Oren Reinstein, Philip E. Johnson & Sergey N. Krylov. (2011) Kinetic Capillary Electrophoresis with Mass-Spectrometry Detection (KCE-MS) Facilitates Label-Free Solution-Based Kinetic Analysis of Protein-Small Molecule Binding. ChemBioChem 12:17, pages 2551-2554.
Crossref
Crossref
Daniel Mucs, Richard A. Bryce & Pascal Bonnet. (2011) Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors. Journal of Computer-Aided Molecular Design 25:6, pages 569-581.
Crossref
Crossref
Mauro Angiolini. (2011) Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis. Future Medicinal Chemistry 3:3, pages 309-337.
Crossref
Crossref
Alexander C. Backes, Gerhard Müller & Peter C. Sennhenn. 2011. Protein Kinases as Drug Targets. Protein Kinases as Drug Targets
145
193
.
Matthias Rabiller, Jeffrey R. Simard & Daniel Rauh. 2011. Protein Kinases as Drug Targets. Protein Kinases as Drug Targets
69
83
.
Doris Hafenbradl, Matthias Baumann & Lars Neumann. 2011. Protein Kinases as Drug Targets. Protein Kinases as Drug Targets
1
43
.
Angelika Dorn, Verena Schattel & Stefan Laufer. (2010) Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 20:10, pages 3074-3077.
Crossref
Crossref
Anita Büttner, Thomas Cottin, Jing Xu, Lito Tzagkaroulaki & Athanassios Giannis. (2010) Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry 18:10, pages 3387-3402.
Crossref
Crossref
Wei-Wei Li, Jin-Juan Chen, Ren-Lin Zheng, Wen-Qin Zhang, Zhi-Xing Cao, Ling-Ling Yang, Xiao-Yu Qing, Liang-Xue Zhou, Li Yang, Luo-Ding Yu, Li-Juan Chen, Yu-Quan Wei & Sheng-Yong Yang. (2010) Taking Quinazoline as a General Support-Nog to Design Potent and Selective Kinase Inhibitors: Application to FMS-like Tyrosine Kinase 3. ChemMedChem 5:4, pages 513-516.
Crossref
Crossref
Matthias Rabiller, Matthäus Getlik, Sabine Klüter, André Richters, Sandra Tückmantel, Jeffrey R. Simard & Daniel Rauh. (2010) Proteus in the World of Proteins: Conformational Changes in Protein Kinases. Archiv der Pharmazie 343:4, pages 193-206.
Crossref
Crossref
Jeffrey R. Simard, Matthäus Getlik, Christian Grütter, Ralf Schneider, Sabine Wulfert & Daniel Rauh. (2010) Fluorophore Labeling of the Glycine-Rich Loop as a Method of Identifying Inhibitors That Bind to Active and Inactive Kinase Conformations. Journal of the American Chemical Society 132:12, pages 4152-4160.
Crossref
Crossref
Richard Morphy. (2009) Selectively Nonselective Kinase Inhibition: Striking the Right Balance. Journal of Medicinal Chemistry 53:4, pages 1413-1437.
Crossref
Crossref
Daniel Rauh. (2010) Inaktive Kinasekonformationen stabilisieren. Nachrichten aus der Chemie 58:2, pages 118-121.
Crossref
Crossref
Jeffrey R. Simard, Vijaykumar Pawar, Beate Aust, Alexander Wolf, Matthias Rabiller, Sabine Wulfert, Armin Robubi, Sabine Klüter, Christian Ottmann & Daniel Rauh. (2009) High-Throughput Screening To Identify Inhibitors Which Stabilize Inactive Kinase Conformations in p38α. Journal of the American Chemical Society 131:51, pages 18478-18488.
Crossref
Crossref
Jeffrey R. Simard, Matthäus Getlik, Christian Grütter, Vijaykumar Pawar, Sabine Wulfert, Matthias Rabiller & Daniel Rauh. (2009) Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors. Journal of the American Chemical Society 131:37, pages 13286-13296.
Crossref
Crossref
Pascal Furet, Joseph Schoepfer, Thomas Radimerski & Patrick Ch?ne. (2009) Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I. Bioorganic & Medicinal Chemistry Letters 19:15, pages 4014-4017.
Crossref
Crossref
Lars Neumann, Allegra Ritscher, Gerhard Müller & Doris Hafenbradl. (2009) Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology. Journal of Computer-Aided Molecular Design 23:8, pages 501-511.
Crossref
Crossref
Matthäus Getlik, Christian Grütter, Jeffrey R. Simard, Sabine Klüter, Matthias Rabiller, Haridas B. Rode, Armin Robubi & Daniel Rauh. (2009) Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc. Journal of Medicinal Chemistry 52:13, pages 3915-3926.
Crossref
Crossref
Jeffrey R Simard, Sabine Klüter, Christian Grütter, Matthäus Getlik, Matthias Rabiller, Haridas B Rode & Daniel Rauh. (2009) A new screening assay for allosteric inhibitors of cSrc. Nature Chemical Biology 5:6, pages 394-396.
Crossref
Crossref